Standardization of amyloid quantitation with florbetapir standardized uptake value ratios to the Centiloid scale

Clinical diagnosis of Alzheimer's disease: Report of the NINCDS‐ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915 · see citing works

The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657 · see citing works

Unified segmentation

Ashburner, J., & Friston, K. J. (2005) · NeuroImage · doi:10.1016/j.neuroimage.2005.02.018 · Cited by 7,507 · see citing works

Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B

Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496 · see citing works

The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET

Klunk, W. E., Koeppe, R. A., Price, J. C., Benzinger, T. L., Devous, M. D., Jagust, W. J., Johnson, K. A., Mathis, C. A., Minhas, D., Pontecorvo, M. J., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.07.003 · Cited by 1,348 · see citing works

Use of Florbetapir-PET for Imaging β-Amyloid Pathology

Clark, C. M. (2011) · JAMA · doi:10.1001/jama.2010.2008 · Cited by 1,117 · see citing works

Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study

Clark, C. M., Pontecorvo, M. J., Beach, T. G., Bedell, B. J., Coleman, R. E., Doraiswamy, P. M., Fleisher, A. S., Reiman, E. M., Sabbagh, M. N., Sadowsky, C. H., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70142-4 · Cited by 855 · see citing works

In Vivo Imaging of Amyloid Deposition in Alzheimer Disease Using the Radioligand ¹⁸ F-AV-45 (Flobetapir F 18)

Wong, D. F., Rosenberg, P. B., Zhou, Y., Kumar, A., Raymont, V., Ravert, H. T., Dannals, R. F., Nandi, A., Brašić, J. R., Ye, W., et al. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.069088 · Cited by 684 · see citing works

Imaging of amyloid β in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism

Rowe, C. C., Ackerman, U., Browne, W. F., Mulligan, R. S., Pike, K. E., O'Keefe, G. J., Tochon‐Danguy, H., Chan, G., Berlangieri, S. U., Jones, G. R., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70001-2 · Cited by 671 · see citing works

Appropriate use criteria for amyloid PET: a report of the amyloid imaging task force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association

Johnson, K. A., Minoshima, S., Bohnen, N. I., Donohoe, K. J., Foster, N. L., Herscovitch, P., Karlawish, J. H., Rowe, C. C., Carrillo, M. C., Hartley, D. M., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.01.002 · Cited by 603 · see citing works

Amyloid-β Imaging with Pittsburgh Compound B and Florbetapir: Comparing Radiotracers and Quantification Methods

Landau, S. M., Breault, C., Joshi, A. D., Pontecorvo, M. J., Mathis, C. A., Jagust, W. J., & Mintun, M. A. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.109009 · Cited by 465 · see citing works

Performance Characteristics of Amyloid PET with Florbetapir F 18 in Patients with Alzheimer's Disease and Cognitively Normal Subjects

Joshi, A. D., Pontecorvo, M. J., Clark, C. M., Carpenter, A. P., Jennings, D. L., Sadowsky, C., Adler, L. P., Kovnat, K. D., Seibyl, J. P., Arora, A., et al. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.090340 · Cited by 391 · see citing works

Measurement of Longitudinal β-Amyloid Change with ¹⁸ F-Florbetapir PET and Standardized Uptake Value Ratios

Landau, S. M., Fero, A., Baker, S. L., Koeppe, R., Mintun, M., Chen, K., Reiman, E. M., & Jagust, W. J. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.148981 · Cited by 364 · see citing works

Phase 1 Study of the Pittsburgh Compound B Derivative 18 F-Flutemetamol in Healthy Volunteers and Patients with Probable Alzheimer Disease

Nelissen, N., Laere, K. V., Thurfjell, L., Owenius, R., Vandenbulcke, M., Koole, M. J. B., Bormans, G. M., Brooks, D. J., & Vandenberghe, R. R. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.063305 · Cited by 331 · see citing works

Brain Amyloid Imaging

Rowe, C. C., & Villemagne, V. L. (2011) · Journal of Nuclear Medicine · doi:10.2967/jnumed.110.076315 · Cited by 275 · see citing works

Partial Volume Correction Strategies in PET

ROUSSET, O. G., Rahmim, A., Alavi, A. A., & Zaidi, H. (2007) · PET Clinics · doi:10.1016/j.cpet.2007.10.005 · Cited by 188 · see citing works

Standardized Expression of 18F-NAV4694 and 11C-PiB β-Amyloid PET Results with the Centiloid Scale

Rowe, C. C., Jones, G. R., Doré, V., Pejoska, S., Margison, L., Mulligan, R. S., Chan, J. G., Young, K., & Villemagne, V. L. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.171595 · Cited by 141 · see citing works

The influence of biological and technical factors on quantitative analysis of amyloid PET: Points to consider and recommendations for controlling variability in longitudinal data

Schmidt, M. E., Chiao, P., Klein, G., Matthews, D. C., Thurfjell, L., Cole, P. E., Margolin, R. A., Landau, S. M., Foster, N. L., Mason, N. S., et al. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.09.004 · Cited by 125 · see citing works

A Semiautomated Method for Quantification of F 18 Florbetapir PET Images

Joshi, A. D., Pontecorvo, M. J., Lu, M., Skovronsky, D., Mintun, M. A., & Devous, M. D. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.153494 · Cited by 92 · see citing works

Quantitative Approaches to Amyloid Imaging

Villemagne, V. L., O'Keefe, G. J., Mulligan, R. S., & Rowe, C. C. (2010) · Methods in molecular biology · doi:10.1007/978-1-60761-901-7_14 · Cited by 5 · see citing works

Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial

Sims, J. R., Zimmer, J. A., Evans, C. D., Lu, M., Ardayfio, P., Sparks, J., Wessels, A. M., Shcherbinin, S., Wang, H., Monkul Nery, E. S., et al. (2023) · JAMA · doi:10.1001/jama.2023.13239 · Cited by 2,932 · see citing works

The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics

Karran, E., & De Strooper, B. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00391-w · Cited by 742 · see citing works

Prevalence of biologically vs clinically defined alzheimer spectrum entities using the National Institute on Aging–Alzheimer's Association Research Framework

Jack, C. R., Therneau, T. M., Weigand, S. D., Wiste, H. J., Knopman, D. S., Vemuri, P., Lowe, V. J., Mielke, M. M., Roberts, R. O., Machulda, M. M., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.1971 · Cited by 300 · see citing works

Validation of amyloid PET positivity thresholds in centiloids: a multisite PET study approach

Initiative, F. T. A. D. N., Royse, S. K., Minhas, D. S., Lopresti, B. J., Murphy, A., Ward, T., Koeppe, R. A., Bullich, S., DeSanti, S., Jagust, W. J., et al. (2021) · Alzheimer's Research & Therapy · doi:10.1186/s13195-021-00836-1 · Cited by 237 · see citing works

Quantification of amyloid PET for future clinical use: a state-of-the-art review

Pemberton, H. G., Collij, L. E., Heeman, F., Bollack, A., Shekari, M., Salvadó, G., Alves, I. L., Garcia, D. V., Battle, M., Buckley, C., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05784-y · Cited by 226 · see citing works

Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer’s disease: a PET substudy interim analysis

Klein, G., Delmar, P., Voyle, N., Rehal, S., Hofmann, C., Abi-Saab, D., Andjelkovic, M., Ristic, S., Wang, G., Bateman, R., et al. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0559-z · Cited by 212 · see citing works

Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial

Shcherbinin, S., Evans, C. D., Lu, M., Andersen, S. W., Pontecorvo, M. J., Willis, B. A., Gueorguieva, I., Hauck, P. M., Brooks, D. A., Mintun, M. A., et al. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2022.2793 · Cited by 210 · see citing works

Comparison of amyloid PET measured in Centiloid units with neuropathological findings in Alzheimer’s disease

Amadoru, S., Doré, V., McLean, C. A., Hinton, F., Shepherd, C. E., Halliday, G. M., Leyton, C. E., Yates, P. A., Hodges, J. R., Masters, C. L., et al. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00587-5 · Cited by 181 · see citing works

PET Neuroimaging of Alzheimer's Disease: Radiotracers and Their Utility in Clinical Research

Bao, W., Xie, F., Zuo, C., Guan, Y., & Huang, Y. H. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.624330 · Cited by 102 · see citing works

Comparison of ¹⁸F‐florbetaben quantification results using the standard Centiloid, MR‐based, and MR‐less CapAIBL^® approaches: Validation against histopathology

Doré, V., Bullich, S., Rowe, C. C., Bourgeat, P., Konate, S., Sabri, O., Stephens, A. W., Barthel, H., Fripp, J., Masters, C. L., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.02.005 · Cited by 93 · see citing works

Association of Initial β-Amyloid Levels With Subsequent Flortaucipir Positron Emission Tomography Changes in Persons Without Cognitive Impairment

Knopman, D. S., Lundt, E. S., Therneau, T. M., Albertson, S. M., Gunter, J. L., Senjem, M. L., Schwarz, C. G., Mielke, M. M., Machulda, M. M., Boeve, B. F., et al. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2020.3921 · Cited by 61 · see citing works

Lanabecestat: Neuroimaging results in early symptomatic Alzheimer’s disease

Zimmer, J. A., Shcherbinin, S., Devous, M. D., Bragg, S. M., Selzler, K. J., Wessels, A. M., Shering, C., Mullen, J., Landry, J., Andersen, S. W., et al. (2021) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12123 · Cited by 27 · see citing works

Comparative evaluation of SUV, tumor-to-blood standard uptake ratio (SUR), and dual time point measurements for assessment of the metabolic uptake rate in FDG PET

Hofheinz, F., van den Hoff, J., Steffen, I. G., Lougovski, A., Ego, K., Amthauer, H., & Apostolova, I. I. (2016) · EJNMMI Research · doi:10.1186/s13550-016-0208-5 · Cited by 44 · see citing works

In Regard to Nair et al

Kataria, T., Basu, T., Gupta, D., et al. (2014) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2014.02.038

Partial Volume Effect Corrected Metabolically Active Tumor Volume From PET for Early-Stage Lung Cancer

Dalah, E. Z., Yang, C., Kainz, K. K., et al. (2013) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2013.06.1394

Reproducibility of proliferation measurements by standardized uptake value of [18F]-fluoro-3'-deoxy-3'-L-fluorothymidine positron emission tomography (PET) in patients with lung cancer

Baek, S., Rhu, J.-S., Oh, S. J., et al. (2007) · Journal of Nuclear Medicine

CONCOMITANT INTRAARTERIAL CHEMORADIOTHERAPY FOR HEAD AND NECK CANCER EVALUATED BY FDG-PET

Kitagawa, Y., Yonekura, Y., Sano, K., et al. (2000) · Japanese jornal of Head and Neck Cancer · doi:10.5981/jjhnc1974.26.116